Analysts Set Expectations for CRDF Q3 Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – HC Wainwright issued their Q3 2026 earnings per share estimates for Cardiff Oncology in a research report issued on Tuesday, September 15th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Cardiff Oncology’s Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.56) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.33) EPS.

Other research analysts have also recently issued research reports about the stock. William Blair cut shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 11th. TD Cowen cut Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Monday, June 1st. Weiss Ratings raised Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 4th. Wall Street Zen upgraded Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th. Finally, Craig Hallum cut Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research report on Wednesday, June 3rd. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Cardiff Oncology has an average rating of “Hold” and a consensus target price of $7.50.

Cardiff Oncology Stock Up 0.7%

Shares of NASDAQ:CRDF opened at $1.35 on Thursday. The company has a market cap of $105.02 million, a PE ratio of -2.25 and a beta of 1.46. The company’s 50-day moving average price is $1.01 and its 200 day moving average price is $1.41. Cardiff Oncology has a fifty-two week low of $0.76 and a fifty-two week high of $3.31.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.06 million.

Institutional Trading of Cardiff Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in CRDF. BlackRock Inc. bought a new stake in Cardiff Oncology during the second quarter worth approximately $1,265,000. Glenview Trust Co bought a new position in Cardiff Oncology during the 2nd quarter valued at $56,000. Capstone Investment Advisors LLC bought a new position in Cardiff Oncology during the 2nd quarter valued at $67,000. Hsbc Holdings PLC acquired a new position in shares of Cardiff Oncology during the 2nd quarter valued at $37,000. Finally, Ieq Capital LLC acquired a new position in shares of Cardiff Oncology during the 2nd quarter valued at $58,000. 16.29% of the stock is currently owned by institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth.

Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer.